Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL

Bookmark and Share
Published: 1 Dec 2018
Views: 694
Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA

Dr Jordan Gauthier speaks to ecancer at ASH 2018 about a comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and/or refractory chronic lymphatic leukaemia.

He describes the methods and findings of the study, as well as the potential impact of the research.

Dr Gauthier explains how this is a relatively small trial, and so this research should be expanded in the future.

Watch Dr Gauthier's press conference here.

Read the article on this work here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.